Unique ID issued by UMIN | UMIN000037421 |
---|---|
Receipt number | R000042538 |
Scientific Title | An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease |
Date of disclosure of the study information | 2019/08/01 |
Last modified on | 2023/07/23 11:25:41 |
A study on improvement of cognitive function by istradefylline for parkinson disease
A study on improvement of cognitive function by istradefylline for parkinson disease
An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease
A study on improvement of cognitive function by istradefylline for parkinson disease
Japan |
Parkinson disease
Neurology |
Others
NO
To validate whether istradefylline improves cognitive function of Parkinson disease.
Efficacy
Primary outcome is digit span test, arithmetic test, verval fluency test, Standard verbal paired-associate learning test, Benton visual retention test. These tests will be evaluated 12weeks later after starting treatment.
Secondary outcomes are Movement Disorder Society-Unified Parkinson Disease Rating Scale(MDS-UPDRS),mini-mental state examination(MMSE), Non-motor symptoms scales and freezing of gait of questionnaire(FOG-Q).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months.
The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.
40 | years-old | <= |
85 | years-old | >= |
Male and Female
1. The patients meet clinically established or clinically probable cases of clinical diagnostic criteria of Parkinson disease by Movement Disorder Society
2. The item of Attention/memory in NMSS is 1 or more.
3. The patient is treated with drugs that include L-dopa
4. The age of patients is 40 to 85years old.
5. Written consent has been obtained.
1. Mini mental state examination (MMSE) is 20 points or less.
2. Istradefylline has been prescribed
25
1st name | Masahiro |
Middle name | |
Last name | Kanai |
Ichinomiya Nishi Hospital
Neurology
494-0001
1, Kaimei-hira, Ichinomiya-city, Aichi, 494-0001, Japan
0586480077
masabilliard35@yahoo.co.jp
1st name | Masahiro |
Middle name | |
Last name | Kanai |
Ichinomiya Nishi Hospital
Neurology
494-0001
1, Kaimei-hira, Ichinomiya-city, Aichi
0586480077
masabilliard35@yahoo.co.jp
Ichinomiya Nishi Hospital
none
Other
Ichinomiya Nishi Hospital
1, Kaimei-hira, Ichinomiya-city, Aichi
0586480077
matsubara@anzu.or.jp
NO
2019 | Year | 08 | Month | 01 | Day |
Unpublished
14
Completed
2019 | Year | 02 | Month | 01 | Day |
2019 | Year | 02 | Month | 15 | Day |
2019 | Year | 08 | Month | 01 | Day |
2021 | Year | 08 | Month | 01 | Day |
2019 | Year | 07 | Month | 18 | Day |
2023 | Year | 07 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042538
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |